What is the translation of " ČAS DO POJAVA " in English?

• time to onset

Examples of using Čas do pojava in Slovenian and their translations into English

Mediana čas do pojava je bil 7,5 dni.
The median time to onset was 7.5 days.

Rezultati so bili podobni kot pri bolnikih z nelaringealnimi napadi HAE glede na čas do pojava lajšanja simptomov.
The results were similar to patients with non-laryngeal attacks of HAE with respect to time to onset of symptom relief.

Čas do pojava lajšanja primarnega simptoma(ure).
Time to Onset of Primary Symptom Relief(hrs).

Primarni opazovani dogodek je bil čas do pojava lajšanja simptomov.
The primary outcome was time to alleviation of symptoms.

Mediani čas do pojava je znašal 0,5 meseca(razpon: 0,0-9,7).
Median time to onset was 0.5 months(range: 0.0-9.7).

Čas do pojava lajšanja simptomov- sestavljena lestvica VAS(ure).
Time to Onset of Symptom Relief-- Composite VAS(hrs).

V integrirani analizi teh nadzorovanih študij 3. faze sta bila čas do pojava lajšanja simptomov in čas do pojava lajšanja primarnega simptoma podobna ne glede na starostno skupino, spol, raso, telesno maso in ne glede na to, ali je bolnik uporabljal androgene ali antifibrinolitične učinkovine ali ne.
In an integrated analysis of these controlled Phase III studies, the time to onset of symptom relief and time to onset of primary symptom relief were similar regardless of age group, sex, race, weight or whether or not the patient used androgens or antifibrinolytic agents.

Čas do pojava odpornosti proti nevirapinu v celični kulturi se ni spremenil, če so nevirapin uporabili v kombinaciji z več drugimi nenukleozidnimi zaviralci reverzne transkriptaze.
Time to emergence of nevirapine resistance in cell culture was not altered when selection included nevirapine in combination with several other NNRTIs.

Mediani čas do pojava je znašal 11,6 tednov(razpon: 2,6-85,1).
Median time to onset was 11.6 weeks(range: 2.6-85.1).

Čas do pojava in trajanje teh simptomov sta lahko povezana z dolgim razpolovnim časom fluoksetina(4- 6 dni) in njegovega aktivnega presnovka, norfluoksetina(4- 16 dni).
The time to occur and the duration of these symptoms may be related to the long half-life of Fluoxetine(4-6 days) and its active metabolite, norfluoxetine(4-16 days).

Mediana čas do pojava sindroma sproščanja citokinov je bil 2 dni.
The median time to onset of a CRS event was 2 days.

Čas do pojava je bil običajno 10-14 dni tako za reakcije, povezane z abakavirjem, kot tudi za tiste, povezane z dolutegravirjem, vendar pa se lahko reakcije na abakavir pojavijo kadar koli v času zdravljenja.
Time to onset was typically 10-14 days for both abacavir and dolutegravir-associated reactions, although reactions to abacavir may occur at any time during therapy.

Mediani čas do pojava teh endokrinopatij je znašal 1,5 meseca(razpon: 0,0-10,1).
Median time to onset of these endocrinopathies was 1.5 months(range: 0.0-10.1).

Mediani čas do pojava teh endokrinopatij je znašal 17,8 tedna(razpon: 6,1-33,1).
Median time to onset of these endocrinopathies was 17.8 weeks(range: 6.1-33.1).

Mediana čas do pojava nevrološkega dogodka pri teh bolnikih je bil 12 dni.
The median time to onset of a neurologic event in these patients was 12 days.

Mediani čas do pojava hude nevtropenije je bil 12 dni, trajala pa je mediano 7 dni.
Median time to onset of severe neutropenia was Day 12 with a median duration of 7 days.

Mediani čas do pojava zmerne do hude anemije je bil 12 dni, trajala pa je mediano sedem dni.
Median time to onset of moderate to severe anaemia was Day 12 with a median duration of 7 days.

Mediani čas do pojava je bil približno 6 dni po prvih 3 zaporednih dnevnih odmerkih zdravila Kepivance; mediano so trajali približno 5 dni.
Median time to onset was approximately 6 days following the first of 3 consecutive daily doses of Kepivance, with a median duration of approximately 5 days.

Mediani čas do pojava prvega SRE v skupini, zdravljeni z zoledronsko kislino, do konca študije ni bil dosežen in je bil značilno daljši kot s placebom(p=0,007).
Median time to onset of the first SRE was not reached in the zoledronic acid-treated arm at the end of the study and was significantly prolonged compared to placebo(p=0.007).

Mediana časa do pojava levkopenije katerekoli stopnje je bila 85 dni.
Median time to onset of any grade leukopenia was 85 days.

Mediana časa do pojava nevtropenije katerekoli stopnje je bila 89 dni.
Median time to onset of any grade neutropenia was 89 days.

Mediana časa do pojava diareje in zaprtja je bila 13 oziroma 17 dni.
Median times to onset for diarrhoea and constipation were 13 and 17 days, respectively.

Mediana časa do pojava hude trombocitopenije je bila 15. dan, mediana trajanja trombocitopenije pa 5 dni.
Median time to onset of severe thrombocytopenia was Day 15 and the median duration was 5 days.

Mediana časa do pojava povečanja vrednosti transaminaz stopnje 3 ali 4 je bila 43 dni.
Median time to onset of increased Grade 3 or 4 transaminases was 43 days.

Mediana vrednost časa do pojava hude trombocitopenije je bila na 15. dan, mediana vrednost trajanja trombocitopenije pa pet dni.
Median time to onset of severe thrombocytopenia was Day 15 and the median duration was five days.

V študijah krizotiniba pri bolnikih z ALK-pozitivnim ali ROS1-pozitivnim NSCLC je bila mediana časa do pojava povečanja vrednosti transaminaz stopnje 1 ali 2 23 dni.
Across studies with crizotinib in patients with either ALK-positive or ROS1-positive NSCLC, median time to onset of increased Grade 1 or 2 transaminases was 23 days.

Opozorilo in previdnostne ukrepe glede tveganja preobčutljivosti, vključno z anafilaksijo, ali za razvoj ADA, s posebnim poudarkom na simptomih, času do pojava in resnosti.
Warning and precautions on the the risk of hypersensitivity including anaphylaxis or ADA development, with particular reference to symptoms, time to onset and severity.

V skupini, zdravljeni z Zometo, mediana časa do pojava prvega SRE ob koncu študije še ni bila dosežena, bila je signifikantno podaljšana v primerjavi s placebom(p=0, 007).
Median time to onset of the first SRE was not reached in the Zometa-treated arm at the end of the study and was significantly prolonged compared to placebo(p=0.007).

Na splošno izkušenje po prihodu zdravila na trg, primeri s kratkim časom do pojava, združljiva kronologija in informacije o primerih izboljšanja ob ukinitvi zdarvila in pojava neželenega učinka ob ponovni uvedbi zdravila, ter dobro dokumentirana poročila nakazujejo vzročno povezanost.
Overall, the information coming from post-marketing experience, cases with short time to onset, compatible chronology, and information of de-challenge and re-challenge cases and the well documented reports, point towards a causal association.